InsidersTradesSigma
Explore the detailed record of transactions filed by Mason Michael, Chief Financial Officer. Officer active across 1 companies, notably Karyopharm Therapeutics Inc.. Aggregated, 6 filings have been published. Total volume traded: €71k. The latest transaction was disclosed on 3 June 2022 — Cession. Regulator: SEC (Form 4). All data is free.
6 of 6 declarations
Michael Mason is the Chief Financial Officer at Karyopharm Therapeutics Inc. In this role, he oversees the company's financial operations and participates in overall strategy. Karyopharm Therapeutics Inc. is a biopharmaceutical company specializing in developing innovative treatments. Michael Mason brings valuable financial expertise to support the company's growth and sustainability.